The protective effect of vitamin D supplementation as adjunctive therapy to antidepressants on brain structural and functional connectivity of patients with major depressive disorder: a randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Growing evidence points to the pivotal role of vitamin D in the pathophysiology and treatment of major depressive disorder (MDD).

However, there is a paucity of longitudinal research investigating the effects of vitamin D supplementation on the brain of MDD patients.

Who Took Part

The study group was 46 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The researchers conducted a double-blind randomized controlled trial in 46 MDD patients, who were randomly allocated into either VD (antidepressant medication + vitamin D supplementation) or NVD (antidepressant medication + placebos) groups.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Major Depressive Disorder, Antidepressive Agents, Vitamin D, Magnetic Resonance Imaging, Diffusion Tensor Imaging, Dietary Supplements and Brain.

The authors tagged it with the keywords functional network connectivity, randomized controlled trial, vitamin D supplementation and white matter integrity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 46 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Psychological medicine), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.